earn report chang price
sequenc consum grew w/ demand mostli due
novaseq also due strength nextseq clinic market
 novaseq consum tripl sequenti
novaseq demand remain robust havent realli touch
custom base major placement onezi twozi
hiseq side
 larg fleet turnov event
novaseq yr upgrad cycl leav plenti runway
guidanc appear overli conserv demand across product
novaseq placement expect bit
subdu vs expect explain
thesi updat tough day watch ugli healthcar
tape brought joy heart via anoth high qualiti quarter
sequenc consum remain star stori array strength
also quit impress think debat whether novaseq
would move needl market oversuppli
ago seem quit remark well although may point
cadenc novaseq placement believ base
channel work conservat function demand rather
strateg decis built upon studi histor custom
behavior elong view technolog cycl see
upsid potenti across sever assumpt turn revenu
forecast move compani guidanc ep also remain
elev furthermor one debat valuat see materi
long term upsid margin potenti genom also
provid ton support termin valu given factor
think remain challeng growth investor
opportun set ahead continu look massiv
technolog threat sight
confer call detail next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 new chip drive consum strength
 sever larg popul genom project ramp
 consum genom busi ramp
 expect novaseq shipment
 slightli
 sequenc system sequenti declin due season
dtc consum strength nipt clinic test help drive growth
servic grew due genotyp servic servic contract
ship ampliseq sampl prep
growth nextseq consum tie strength/growth clinic market
iseq start ship
 imagin much cannib miniseq w/ iseq
hiseq box retir
elev pull-through rate nextseq emerg workhors box clinic market lot clinic demand show
nextseq side
ship high highest shipment lead ship
 shipment hiseq custom custom howev everi custom purchas
 expect custom replac fleet end
order new-to-ilmn sequenc g/translat lab benchtop sequenc clinic test
expect shipment measur upgrad cycl play yr
new custom get access novaseq enabl sequenc larger studi cohort deeper
sequenc liquid biopsi broader sequenc consortium includ wg addit we
differ address much larger target market make comparison difficult launch
million except per share data fy end decemb sequenc organ gp less op less ep share inc net inc price-to-earnings prem disc januari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
